false000140370800014037082024-10-162024-10-16

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 16, 2024

 

 

EVOKE PHARMA, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-36075

20-8447886

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

420 Stevens Avenue, Suite 230

 

Solana Beach, California

 

92075

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 858 345-1494

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

EVOK

 

The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On October 16, 2024, Evoke Pharma, Inc. (the “Company”) entered into the Seventh Amendment to Lease (the “Seventh Amendment”) with SB Corporate Centre III-IV, LLC (the “Landlord”), to amend the Office Lease Agreement, dated as of December 19, 2016, by and between the Landlord and the Company (as amended, the “Lease”), relating to office space located at 420 Stevens Avenue, Suite 230, Solana Beach, California 92075, which serves as the Company’s headquarters. The Seventh Amendment extends the term of the Lease from October 31, 2024 to March 31, 2027. The Seventh Amendment provides that the base monthly rent for the leased space will be $6,456.95 from November 1, 2024 to October 31, 2025, $6,650.66 from November 1, 2025 to October 31, 2026 and $6,850.18 from November 1, 2026 to March 31, 2027, and that the Company will be obligated to pay a specified percentage of certain expenses paid by the Landlord. The Company will also be granted a one-month rent abatement for November 2024, provided there is no material default under the Lease.

The foregoing description of the Seventh Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Seventh Amendment, which will be filed as an exhibit to the Company’s Form 10-K to be filed for the year ended December 31, 2024.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

EVOKE PHARMA, INC.

 

 

 

 

Date:

 October 17, 2024

By:

/s/ Matthew J. D'Onofrio

 

 

 

Name: Matthew J. D'Onofrio
Title: Chief Executive Officer

 

v3.24.3
Document And Entity Information
Oct. 16, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 16, 2024
Entity Registrant Name EVOKE PHARMA, INC.
Entity Central Index Key 0001403708
Entity Emerging Growth Company false
Entity File Number 001-36075
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 20-8447886
Entity Address, Address Line One 420 Stevens Avenue, Suite 230
Entity Address, City or Town Solana Beach
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92075
City Area Code 858
Local Phone Number 345-1494
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol EVOK
Security Exchange Name NASDAQ
Evoke Pharma (NASDAQ:EVOK)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Evoke Pharma Charts.
Evoke Pharma (NASDAQ:EVOK)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Evoke Pharma Charts.